Search Results - "Man, Johnathan"

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis by Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin

“…We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. Randomized trials…”
Get more information

Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort study by Purdie, Stuart, Creighton, Nicola, White, Kahren Maree, Baker, Deborah, Ewald, Dan, Lee, Chee Khoon, Lyon, Alison, Man, Johnathan, Michail, David, Miller, Alexis Andrew, Tan, Lawrence, Currow, David, Young, Jane M.

“…Little has been published on the diagnostic and referral pathway for lung cancer in Australia. This study set out to quantify general practitioner (GP) and…”
Get full text

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis by Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Cooper, Wendy, Links, Matthew, Gebski, Val, Herbst, Roy S, Gralla, Richard J, Mok, Tony, Yang, James Chih-Hsin

“…Checkpoint inhibitors have replaced docetaxel as the new standard second-line therapy in advanced non-small cell lung carcinoma (NSCLC), but little is known…”
Get more information

Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis by Ritchie, Georgia, Gasper, Harry, Man, Johnathan, Lord, Sally, Marschner, Ian, Friedlander, Michael, Lee, Chee Khoon

“…Checkpoint inhibitors have a unique mechanism of action that differs from chemotherapy or targeted therapies. The validity of objective response rate (ORR) as…”
Get more information

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials by Man, Johnathan, Millican, Jared, Mulvey, Arthur, Gebski, Val, Hui, Rina

“…Expression of programmed cell death ligand 1 (PD-L1) on tumor cells with or without immune cells is widely reported in clinical trials of programmed cell death…”
Get full text

Treatment‐related toxicities of immune checkpoint inhibitors in advanced cancers: A meta‐analysis by Man, Johnathan, Ritchie, Georgia, Links, Matthew, Lord, Sally, Lee, Chee Khoon

“…Background We performed a meta‐analysis to quantify toxic death, adverse events (AEs) and treatment discontinuation due to AEs from checkpoint inhibitors (CI)…”
Get full text

Reply to Q. Wu et al by Man, Johnathan, Ritchie, Georgia, Links, Matthew, Lord, Sarah, Lee, Chee Khoon

Get full text